Press Association -- Two drugs to treat breast cancer have been rejected for use on the NHS when combined with other therapies, according to new guidance. The National Institute for Health and Clinical Excellence (Nice) turned down Tyverb (lapatinib) and Herceptin (trastuzumab) when used in combination with an aromatase inhibitor (another type of breast cancer treatment).
